Analysts expect Voyager Therapeutics, Inc. (NASDAQ:VYGR) to announce sales of $5.05 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Voyager Therapeutics’ earnings, with the highest sales estimate coming in at $6.71 million and the lowest estimate coming in at $1.50 million. Voyager Therapeutics posted sales of $2.36 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 114%. The company is expected to announce its next earnings results on Wednesday, March 21st.

According to Zacks, analysts expect that Voyager Therapeutics will report full year sales of $5.05 million for the current fiscal year, with estimates ranging from $4.70 million to $12.00 million. For the next fiscal year, analysts expect that the company will post sales of $15.30 million per share, with estimates ranging from $6.00 million to $32.20 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Voyager Therapeutics.

Several research firms recently issued reports on VYGR. Raymond James Financial, Inc. began coverage on shares of Voyager Therapeutics in a research report on Thursday, October 12th. They issued an “outperform” rating and a $35.00 price target for the company. Stifel Nicolaus reissued a “buy” rating and issued a $31.00 price target (up previously from $20.00) on shares of Voyager Therapeutics in a research report on Monday, October 23rd. Robert W. Baird began coverage on shares of Voyager Therapeutics in a research report on Monday, October 30th. They issued an “outperform” rating and a $31.00 price target for the company. Wedbush reissued a “positive” rating and issued a $31.00 price target (down previously from $36.00) on shares of Voyager Therapeutics in a research report on Tuesday, October 31st. Finally, Chardan Capital reissued a “hold” rating and issued a $17.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, October 31st. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. Voyager Therapeutics currently has an average rating of “Hold” and an average target price of $27.88.

TRADEMARK VIOLATION NOTICE: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/11/14/zacks-analysts-expect-voyager-therapeutics-inc-vygr-will-announce-quarterly-sales-of-5-05-million.html.

In other news, insider Bernard Ravina sold 16,470 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $12.87, for a total transaction of $211,968.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have sold 38,430 shares of company stock valued at $562,890. Company insiders own 8.00% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP increased its holdings in shares of Voyager Therapeutics by 7.9% during the third quarter. Dimensional Fund Advisors LP now owns 105,914 shares of the company’s stock worth $2,181,000 after buying an additional 7,786 shares in the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of Voyager Therapeutics by 71.5% during the third quarter. Schwab Charles Investment Management Inc. now owns 49,788 shares of the company’s stock worth $1,026,000 after buying an additional 20,753 shares in the last quarter. Mckinley Capital Management LLC Delaware acquired a new stake in shares of Voyager Therapeutics during the third quarter worth approximately $1,412,000. Wells Fargo & Company MN increased its holdings in shares of Voyager Therapeutics by 312.8% during the third quarter. Wells Fargo & Company MN now owns 377,190 shares of the company’s stock worth $7,766,000 after buying an additional 285,806 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new stake in shares of Voyager Therapeutics during the third quarter worth approximately $5,155,000. 40.93% of the stock is owned by institutional investors.

Voyager Therapeutics (NASDAQ:VYGR) opened at $12.26 on Tuesday. Voyager Therapeutics has a 52-week low of $8.10 and a 52-week high of $25.99.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.